Peregrine Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Peregrine Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-87,500	Closed	-$5.51M	–	320
2020 Q1	$5.51M	Buy	87,500 +32	+0%	+$2.88K	0.2%	148
2019 Q4	$10.8M	Sell	87,468 -80,434	-48%	-$7.2M	0.28%	138
2019 Q3	$11.1M	Buy	167,902 +38,556	+30%	+$2.59M	0.3%	132
2019 Q2	$10.3M	Buy	129,346 +17,259	+15%	+$1.54M	0.25%	150
2019 Q1	$12.5M	Buy	112,087 +4,534	+4%	+$495K	0.31%	140
2018 Q4	$10.8M	Buy	107,553 +7,615	+8%	+$789K	0.31%	138
2018 Q3	$12.6M	Sell	99,938 -51,496	-34%	-$5.45M	0.3%	137
2018 Q2	$12.7M	Buy	151,434 +36,189	+31%	+$2.65M	0.32%	131
2018 Q1	$7.09M	Sell	115,245 -5,512	-5%	-$332K	0.17%	206
2017 Q4	$7.05M	Buy	+120,757	New	+$7.62M	0.17%	223

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Peregrine Capital Management's ICPT Position: Q2 2020 in Review

Peregrine Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2020, closing a stake of 87,500 shares — an estimated $5.51M sold.

Peregrine Capital Management first reported a position in ICPT in Q4 2017 and held it in 10 quarters. The position peaked at $12.7M in Q2 2018. 192 funds tracked by Wall St. Rank hold ICPT as of Q2 2020.

Peregrine Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Peregrine Capital Management sold 87,500 Intercept Pharmaceuticals, Inc. shares in Q2 2020, an estimated $5.51M.
Peregrine Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2017 and held it in 10 quarters.
Peregrine Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $12.7M in Q2 2018.
192 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2020.

Based on Peregrine Capital Management's 13F filing for Q2 2020, filed 30 Jul 2020.